Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Skyepharma.

  • Webinars & Exhibitions

  • GEOMATRIX - Multi-layer Tablet Technology

  • GEOCLOCK - Press-coated Tablet (Tab-in-Tab)

  • SOCTEC - ER Gastro-retentive Technology

  • Bottle Packaging Capabilities

  • Blister Contract Packaging Services

  • Pharmaceutical Packaging Services

  • Pharmaceutical Serialization & Aggregation

  • Immediate & Modified Release Tablets

  • Controlled Drug Delivery Expertise

  • Highly Potent Tablet Manufacturing

  • High Potency Capsule Manufacturing

  • Modified Release Capsule Products

  • Controlled Substance Formulation Development

  • Complex OSD Manufacturing

  • Orally Disintegrating Tablet Manufacturing

  • Chewable Tablet Manufacturing

PharmaCompass
Skyepharma RM
Skyepharma
France Flag
Country
Country
France
Address
Address
55 Rue du Montmurier, 38070 Saint-Quentin-Fallavier
Telephone
Telephone
+33 4 74 95 20 20
Twitter
Twitter
Contact Info
Others

Details:

Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.


Lead Product(s): 20-Hydroxyecdysone

Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Biophytis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 25, 2023

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

The facility will aim to produce several thousand enemas of the Company’s lead candidate (MaaT013) for Graft-versus-Host disease and capsules of its second drug candidate (MaaT033) designed to improve survival in patients receiving allogeneic stem cell transplantation.


Lead Product(s): MaaT013

Therapeutic Area: Immunology Product Name: MaaT013

Highest Development Status: Phase IIIProduct Type: Large molecule

Recipient: MaaT Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 08, 2022

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicological studies.


Lead Product(s): Cannabidiol,Isoflurane

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Incannex Healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 22, 2021

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

IPA-001 is inhaled formulation displayed viricidal activity against SARS-CoV2 after 5 minutes contact time. It is purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 virus in vitro.


Lead Product(s): IPA-001

Therapeutic Area: Infections and Infectious Diseases Product Name: IPA-001

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Inspira

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 06, 2021

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Hikma will immediately resume launch activities of its generic product for Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.


Lead Product(s): Fluticasone Propionate,Salmeterol Xinafoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Fluticasone Propionate/Salmeterol-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2021

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

The new device is an evolution of Vectura’s lever-operated multi-dose (LOMI) device and builds on Vectura and Hikma’s shared experience with the generic Advair Diskus® programme, enabling accelerated development under this agreement.


Lead Product(s): Fluticasone Propionate,Salmeterol Xinafoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Fluticasone Propionate/Salmeterol-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

Deal Size: $95.0 million Upfront Cash: $15.0 million

Deal Type: Agreement December 17, 2020

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.


Lead Product(s): VR588

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VR588

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Kinaset Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 30, 2020

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Fluticasone Propionate / Salmeterol or VR315 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.


Lead Product(s): Fluticasone Propionate,Salmeterol Xinafoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VR315

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 22, 2020

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

Vectura will support the development of a single use device/formulation combination for evaluation in Phase I of inhaled oxytocin, and then expedite technical transfer to a commercial manufacturer to advance to Phase III and commercial launch.


Lead Product(s): Oxytocin

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Peptide

Partner/Sponsor/Collaborator: Monash University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 14, 2020

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier

Details:

QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.


Lead Product(s): Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Enerzair Breezhaler

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Skyepharma Company Banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY